AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27872863 — intervention group
Group type: COMPARATOR
Intervention: sustained-release methylphenidate
Number of subjects: 38
Study 24136652 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive-type moderate-resistance training (EMRT) for 12 weeks
Number of subjects: 0
Study 24136652 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive-type moderate-resistance training (EMRT)
Number of subjects: 0
Study 22531559 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) with Sighs (30 cm H2O peak airway pressure, administered once per minute)
Number of subjects: 20
Study 22531559 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) with Sighs
Number of subjects: 20
Study 20491708 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning strategies
Number of subjects: 126
Study 20491708 — intervention group
Group type: COMPARATOR
Intervention: Positioning plus Safe T Sleep™ positioning wrap
Number of subjects: 126
Study 18829790 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum and Lactobacillus acidophilus added to breast milk or mixed feeding, twice daily for 6 weeks
Number of subjects: 434
Study 18829790 — intervention group
Group type: COMPARATOR
Intervention: Breast milk or mixed feeding (control group)
Number of subjects: 434
Study 15549624 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous absorbable sutures (4-0 polyglactin 910)
Number of subjects: 60
Study 15549624 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular absorbable sutures (4-0 polyglactin 910)
Number of subjects: 60
Study 15549624 — intervention group
Group type: COMPARATOR
Intervention: Adhesive papertape
Number of subjects: 60
Study 12425849 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 50% nitrous oxide and oxygen
Number of subjects: 30
Study 12425849 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of air and oxygen (Control)
Number of subjects: 30
Study 10347295 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Sclerotherapy (EIS), n = 55
Number of subjects: 157
Study 10347295 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Ligation (EVL), n = 52
Number of subjects: 157
Study 10347295 — intervention group
Group type: COMPARATOR
Intervention: Nontreated Control Group, n = 50
Number of subjects: 157
Study 8538445 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalization and instructions to search for the rules in the simple task
Number of subjects: 0
Study 8538445 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalization and instructions to search for the rules in the complex task
Number of subjects: 0
Study 8538445 — intervention group
Group type: COMPARATOR
Intervention: Observational-learning condition in the simple task
Number of subjects: 0
Study 8538445 — intervention group
Group type: COMPARATOR
Intervention: Observational-learning condition in the complex task
Number of subjects: 0
Study 1956211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (40 mg/day)
Number of subjects: 28
Study 1956211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day)
Number of subjects: 28
Study 1956211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31227872 — intervention group
Group type: COMPARATOR
Intervention: ARID5B SNPs (rs10821936, rs10994982, rs7089424, rs2393732, rs2393782, rs2893881, rs4948488)
Number of subjects: 298
Study 31227872 — intervention group
Group type: COMPARATOR
Intervention: CAG haplotype (rs10821936, rs10994982, rs7089424)
Number of subjects: 298
Study 31227872 — intervention group
Group type: COMPARATOR
Intervention: G allele at rs2893881
Number of subjects: 298
Study 29308593 — intervention group
Group type: EXPERIMENTAL
Intervention: ADF IR formulation of an opioid
Number of subjects: 24
Study 29308593 — intervention group
Group type: COMPARATOR
Intervention: Marketed IR formulation
Number of subjects: 24
Study 24777621 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic food supplement (Lactobacillus rhamnosus R0011 1.9×10^9 cfu and L. acidophilus R0052 0.1×10^9 cfu/d for 7 days)
Number of subjects: 112
Study 24777621 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (oral rehydration solution and zinc)
Number of subjects: 112
Study 24777621 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic food supplement
Number of subjects: 112
Study 23586657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg administered three times per day for 48 hours
Number of subjects: 30
Study 23586657 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered three times per day for 48 hours
Number of subjects: 30
Study 21473840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) before laser preparation
Number of subjects: 10
Study 21473840 — intervention group
Group type: COMPARATOR
Intervention: Non-LLT (without low level laser therapy) before laser preparation
Number of subjects: 10
Study 19770393 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 10 microg/kg, n=26
Number of subjects: 52
Study 19770393 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=26
Number of subjects: 52
Study 19770393 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 52
Study 19770393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 17324738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 5 mg (n = 18)
Number of subjects: 40
Study 17324738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 40
Study 17324738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (after 14 days)
Number of subjects: 40
Study 17324738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after 14 days)
Number of subjects: 40
Study 17324738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 40
Study 17324738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15155205 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (300 mg) and Ritonavir (100 mg) QD + Tenofovir DF QD (from day 15)
Number of subjects: 11
Study 15155205 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir (300 mg) and Ritonavir (100 mg) QD
Number of subjects: 11
Study 11495174 — intervention group
Group type: EXPERIMENTAL
Intervention: DRT plus life-skills training
Number of subjects: 144
Study 11495174 — intervention group
Group type: EXPERIMENTAL
Intervention: DRT plus booster sessions
Number of subjects: 144
Study 11495174 — intervention group
Group type: EXPERIMENTAL
Intervention: DRT plus life-skills training and booster sessions
Number of subjects: 144
Study 11495174 — intervention group
Group type: COMPARATOR
Intervention: DRT only
Number of subjects: 144
Study 9710007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant T-cell clones in patients with idiopathic sensory neuropathies
Number of subjects: 20
Study 9710007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant T-cell clones in chronic idiopathic axonal polyneuropathy (CIAP)
Number of subjects: 20
Study 9710007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant T-cell clones in chronic idiopathic ataxic neuropathy (CIAN)
Number of subjects: 20
Study 9710007 — intervention group
Group type: COMPARATOR
Intervention: Elderly normal controls
Number of subjects: 20
Study 9710007 — intervention group
Group type: COMPARATOR
Intervention: Elderly controls with degenerative neurologic diseases
Number of subjects: 20
Study 9710007 — intervention group
Group type: COMPARATOR
Intervention: Elderly patients with idiopathic chronic inflammatory demyelinating polyneuropathy
Number of subjects: 20
Study 7991905 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5‐2.5 mg/kg for induction; 6‐12 mg/kg continuous infusion for maintenance)
Number of subjects: 30
Study 7991905 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptanalgesia (sodium thiopental 4‐5 mg/kg for induction; droperidol 0.15 microgram/kg/h and 50% N2O/O2 for maintenance)
Number of subjects: 30
Study 2903110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa (5-aminosalicylic acid) 1500 mg t.i.d. (three times a day)
Number of subjects: 75
Study 2903110 — intervention group
Group type: COMPARATOR
Intervention: Salazopyrin (sulfasalazine) 3 g t.i.d.
Number of subjects: 75
Study 31366394 — intervention group
Group type: EXPERIMENTAL
Intervention: bCPAP
Number of subjects: 0
Study 31366394 — intervention group
Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 0
Study 28745686 — intervention group
Group type: EXPERIMENTAL
Intervention: LPD (0.6 g of protein per kg of body weight/day) with keto/amino acid ketosteril (1 tablet per 5 kg of body weight/day)
Number of subjects: 90
Study 28745686 — intervention group
Group type: EXPERIMENTAL
Intervention: LPD (0.6 g of protein per kg of body weight/day) with keto/amino acid ketoaminol (1 tablet per 5 kg of body weight/day)
Number of subjects: 90
Study 28745686 — intervention group
Group type: COMPARATOR
Intervention: LPD without keto/amino acids (control group)
Number of subjects: 90
Study 26182929 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-fatigue mat
Number of subjects: 16
Study 26182929 — intervention group
Group type: COMPARATOR
Intervention: Normal rigid surface
Number of subjects: 16
Study 24120216 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) 600 mg once-daily
Number of subjects: 168
Study 24120216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) 400 mg once-daily
Number of subjects: 168
Study 24120216 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 168
Study 21994958 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1-84)
Number of subjects: 97
Study 21994958 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 97
Study 18268174 — intervention group
Group type: COMPARATOR
Intervention: Control group (follow-up by a cardiologist)
Number of subjects: 1023
Study 18268174 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic support group (nurse support)
Number of subjects: 1023
Study 18268174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive support group (nurse support)
Number of subjects: 1023
Study 17154666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with beta-lactam plus macrolide
Number of subjects: 0
Study 17154666 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with respiratory fluoroquinolone
Number of subjects: 0
Study 17154666 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam monotherapy
Number of subjects: 0
Study 17154666 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam alone at adequate dosage
Number of subjects: 0
Study 14555558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilo‐Neb/Aerotrap nebulizer
Number of subjects: 12
Study 14555558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventstream nebulizer
Number of subjects: 12
Study 14555558 — intervention group
Group type: EXPERIMENTAL
Intervention: HaloLite nebulizer
Number of subjects: 12
Study 14555558 — intervention group
Group type: EXPERIMENTAL
Intervention: All nebulizers (Ilo‐Neb/Aerotrap, Ventstream, HaloLite)
Number of subjects: 12
Study 11012656 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivicaine
Number of subjects: 92
Study 11012656 — intervention group
Group type: COMPARATOR
Intervention: Saline (dummy injection)
Number of subjects: 92
Study 11012656 — intervention group
Group type: COMPARATOR
Intervention: No injection
Number of subjects: 92
Study 9120111 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40
Study 9120111 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 9120111 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and Propofol
Number of subjects: 40
Study 1428132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (IT‐MTX) with cranial radiotherapy (RT)
Number of subjects: 76
Study 1428132 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal methotrexate (IT‐MTX) alone
Number of subjects: 76
Study 3917884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate infusion
Number of subjects: 10
Study 3917884 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution (saline) infusion
Number of subjects: 10
Study 31301739 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist assessment
Number of subjects: 69
Study 31301739 — intervention group
Group type: COMPARATOR
Intervention: Physician assessment
Number of subjects: 69
Study 31301739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both assessments (physiotherapist and physician)
Number of subjects: 69
Study 28865067 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment in sleep unit (SU) setting
Number of subjects: 191
Study 28865067 — intervention group
Group type: COMPARATOR
Intervention: CPAP treatment in primary care (PC) setting
Number of subjects: 191
Study 26257209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM) training
Number of subjects: 40
Study 26257209 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 24666929 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (30 minutes of Turkish art music during hemodialysis sessions, 12 total sessions)
Number of subjects: 60
Study 24666929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 60
Study 22186709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group intervention (Vitality Training Programme - VTP)
Number of subjects: 73
Study 22186709 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care plus a CD for voluntary use with mindfulness-based home exercises)
Number of subjects: 73
Study 20102888 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (low-dose bisoprolol regimen started ≥30 days before surgery)
Number of subjects: 3884
Study 20102888 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker therapy (control group)
Number of subjects: 3884
Study 20102888 — intervention group
Group type: EXPERIMENTAL
Intervention: History of stroke
Number of subjects: 3884
Study 20102888 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 3884
Study 20102888 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 3884
Study 20102888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol therapy
Number of subjects: 3884
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus fluoxetine
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus paroxetine
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐deprenyl
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 17469694 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium EDTA
Number of subjects: 0
Study 16036038 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of atrial fibrillation post-myocardial infarction
Number of subjects: 0
Study 16036038 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis treatment
Number of subjects: 0
Study 12073958 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG), measured 4 times daily using a reflectance meter with memory
Number of subjects: 58
Study 12073958 — intervention group
Group type: COMPARATOR
Intervention: Control group with periodic monitoring at prenatal visits
Number of subjects: 58
Study 12073958 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 58
Study 9796636 — intervention group
Group type: EXPERIMENTAL
Intervention: PXM 10 mg every other day (q.o.d.)
Number of subjects: 43
Study 9796636 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 0.5 g/m2
Number of subjects: 43
Study 9796636 — intervention group
Group type: EXPERIMENTAL
Intervention: PXM 10 mg q.o.d.
Number of subjects: 43
Study 9796636 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO/PXM combination
Number of subjects: 43
Study 9796636 — intervention group
Group type: EXPERIMENTAL
Intervention: PXM alone
Number of subjects: 43
Study 9796636 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO/PXM
Number of subjects: 43
Study 9796636 — intervention group
Group type: EXPERIMENTAL
Intervention: PXM/DFMO
Number of subjects: 43
Study 7662205 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently diagnosed HIV-positive men (within 2-4 months)
Number of subjects: 684
Study 7662205 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic men
Number of subjects: 684
Study 7662205 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic men
Number of subjects: 684
Study 7662205 — intervention group
Group type: EXPERIMENTAL
Intervention: Men diagnosed less recently
Number of subjects: 684
Study 7662205 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal reactions of those informed
Number of subjects: 684
Study 2748112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery alone
Number of subjects: 68
Study 2748112 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surgery (cataract surgery with posterior lip sclerectomy or trabeculectomy)
Number of subjects: 68
Study 702248 — intervention group
Group type: EXPERIMENTAL
Intervention: Transported by a trained physician and nurse
Number of subjects: 0
Study 30985930 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related medical rehabilitation (intervention group)
Number of subjects: 484
Study 30985930 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical rehabilitation (control group)
Number of subjects: 484
Study 27933424 — intervention group
Group type: EXPERIMENTAL
Intervention: New Beginnings Program (NBP)
Number of subjects: 477
Study 26825640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 12
Study 26825640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24477618 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of α‐lipoic acid (ALA) 600 mg and superoxide dismutase (SOD) 140 IU daily with physiotherapy
Number of subjects: 96
Study 24477618 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 96
Study 23257368 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding stent (STENTYS, STENTYS SA, Paris, France)
Number of subjects: 80
Study 23257368 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable stent (VISION, Abbott Vascular, Santa Clara, California; or Driver, Medtronic, Minneapolis, Minnesota)
Number of subjects: 80
Study 20622702 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus Progressives
Number of subjects: 20
Study 20622702 — intervention group
Group type: COMPARATOR
Intervention: PureVision Multifocal
Number of subjects: 20
Study 17955550 — intervention group
Group type: EXPERIMENTAL
Intervention: Long interval regimen (dornase alfa nebulization with >6 hr dwell time)
Number of subjects: 20
Study 17955550 — intervention group
Group type: COMPARATOR
Intervention: Short interval regimen (dornase alfa nebulization with ≤6 hr dwell time)
Number of subjects: 20
Study 15992517 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified plant stanols (2 to 3 g/day) incorporated in margarines or spreads
Number of subjects: 0
Study 15992517 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified plant stanols in low-fat food products
Number of subjects: 0
Study 12815797 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (LP) at 7 mmHg
Number of subjects: 82
Study 10102975 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg ranitidine
Number of subjects: 20
Study 10102975 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg famotidine
Number of subjects: 20
Study 10102975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7568481 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg
Number of subjects: 859
Study 7568481 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.1 mg/kg plus ketamine 0.4 to 0.5 mg/kg
Number of subjects: 859
Study 2174783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) s.c. every 12 h, initial dose about 100 U/kg bodyweight
Number of subjects: 71
Study 2174783 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 71
Study 7305609 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 23
Study 7305609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31154309 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week intervention comprising the provision of free plant-based meat alternatives, written information on health and environmental benefits, success stories, and recipes.
Number of subjects: 0